---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056940"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:59:02.611559+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xenon Q1 net loss $47.9M; MDD Phase 3 on track for H2 2024 start

## Summary
- Net loss of $47.9M for Q1 2024, up from $41.7M in Q1 2023; cash and securities $885.4M.
- R&D expenses rose to $44.3M from $39.5M, driven by azetukalner manufacturing and personnel costs.
- Phase 3 MDD program to start H2 2024 after successful FDA interactions; X-TOLE2 enrollment completion expected late 2024 to early 2025.
- WHO and USAN approved 'azetukalner' as generic name for XEN1101, a Kv7 potassium channel opener.
- Other income increased to $11.5M from $7.6M on higher interest; cash expected to fund operations into 2027.

## SEC filing metadata
- accession: 0000950170-24-056940
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000095017024056940/0000950170-24-056940-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000095017024056940/xene-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056940
- JSON: https://secwatch.observer/filing/0000950170-24-056940.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056940.txt

## Key facts
- Earnings Releases
  Xenon Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2024.
  - Period: the first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 9, 2024, Xenon Pharmaceuticals Inc. (the “Company”) announced via press release the Company’s financial results for the three months ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582313/000095017024056940/0000950170-24-056940-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.